Parkman Healthcare Partners LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR – Free Report) during the second quarter, HoldingsChannel reports. The institutional investor bought 2,416,518 shares of the company’s stock, valued at approximately $1,692,000. Parkman Healthcare Partners LLC owned about 0.05% of InspireMD as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Velan Capital Investment Management LP boosted its holdings in shares of InspireMD by 137.1% in the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after purchasing an additional 1,239,669 shares during the period. Nantahala Capital Management LLC increased its holdings in InspireMD by 45.7% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock worth $8,137,000 after purchasing an additional 1,058,467 shares during the period. Orbimed Advisors LLC increased its holdings in InspireMD by 46.9% during the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after purchasing an additional 1,000,000 shares during the period. Soleus Capital Management L.P. raised its position in InspireMD by 99.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock valued at $4,282,000 after purchasing an additional 940,831 shares in the last quarter. Finally, Ingalls & Snyder LLC raised its position in InspireMD by 70.8% during the 4th quarter. Ingalls & Snyder LLC now owns 384,300 shares of the company’s stock valued at $684,000 after purchasing an additional 159,298 shares in the last quarter. Institutional investors own 44.78% of the company’s stock.
InspireMD Stock Performance
Shares of NSPR opened at $0.87 on Tuesday. The company has a 50 day moving average price of $0.74 and a 200-day moving average price of $1.16. InspireMD, Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $2.56. The stock has a market capitalization of $40.44 million, a PE ratio of -1.16 and a beta of 0.81.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on NSPR
About InspireMD
InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.
The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.
Read More
- Five stocks we like better than InspireMD
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding NSPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InspireMD, Inc. (NYSE:NSPR – Free Report).
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.
